Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 23Head & Neck 4Breast 4Thoracic 3Genitourinary 3CNS 3Lymphoid 2Gynecologic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Other 1Dermatologic 1

Conditions

Sarcoma 26Gliosarcoma 22Glioblastoma 21Glioma 16Ependymoma 15Astrocytoma 12Osteosarcoma 11Oligodendroglioma 11Central Nervous System Neoplasms 10Rhabdomyosarcoma 9Medulloblastoma 9Sarcoma, Ewing 7Neuroblastoma 7Glioma, Subependymal 7Brain Neoplasms 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Carcinosarcoma 6Wilms Tumor 5Liposarcoma 5Hepatoblastoma 5Carcinoma, Transitional Cell 5Sarcoma, Kaposi 4Ovarian Neoplasms 4Meningioma 4

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Magnetic Resonance Spectroscopy × Sarcoma × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡